公开(公告)号：US5418154A

公开(公告)日：1995-05-23

申请号：US997770

申请日：1992-12-24

Applicant: Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

IPC: A61F2/02 ,  A61J3/07 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/22 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61J3/07 ,  A61K35/22 ,  A61K35/30 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/5089 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30 ,  Y10S530/817

Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biologically active factor, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through the inner bore and the polymeric casting solution is extruded through the outer bore. The method involves initiating extrusion of the coagulant subsequent to initiating delivery of the casting solution through the respective bores to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time.

Abstract translation: 包含生物材料的细长无缝胶囊通过以下方法制备，其中包括细胞悬浮液或其它生物活性因子的凝结剂和聚合物浇铸溶液通过具有至少两个同心孔的共同挤出口挤出，使得凝结剂 通过内孔挤出，并且聚合物浇铸溶液通过外孔挤出。 该方法包括在引发浇铸溶液通过相应的孔之后引发凝结剂的挤出，以形成具有弯曲且光滑的前缘形状的胶囊。 然后关闭凝结剂的输送，并且立即或在一些预定时间之后终止浇注溶液的挤出。

公开(公告)号：US5389535A

公开(公告)日：1995-02-14

申请号：US169169

申请日：1993-12-17

Applicant: Patrick Aebischer ,  Lars Wahlberg

Inventor： Patrick Aebischer ,  Lars Wahlberg

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K35/12 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08 ,  C12M1/40

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K35/12 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61K2035/126 ,  A61K2035/128 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Methods and systems are disclosed for encapsulating viable cells which produce biologically-active factors. The cells are encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores, such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links.

Abstract translation: 公开了用于包封产生生物活性因子的活细胞的方法和系统。 通过将水性细胞悬浮液和聚合物溶液共挤出通过共同的口以形成具有封装细胞悬浮液的聚合物外涂层的管状挤出物，将细胞包封在半透膜聚合物膜内。 例如，细胞悬浮液和聚合物溶液可以通过具有至少两个同心孔的共同挤出口挤出，使得细胞悬浮液通过内孔挤出并且聚合物溶液通过外孔挤出。 聚合物溶液凝结形成外涂层。 当形成外涂层时，管状挤出物的端部可被密封以形成电池盒。 在一个实施方案中，管状挤出物间隔密封以限定通过聚合物连接物连接的分离的细胞室。

公开(公告)号：US5158881A

公开(公告)日：1992-10-27

申请号：US461999

申请日：1990-01-08

Applicant: Patrick Aebischer ,  Lars Wahlberg

Inventor： Patrick Aebischer ,  Lars Wahlberg

IPC: A61J3/07 ,  A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/13 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0024 ,  A61F2/022 ,  A61K35/13 ,  A61K9/0085 ,  A61K9/0092 ,  A61K9/4816 ,  A61K9/4833 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Methods and systems are disclosed for encapsulating viable cells which produce biologically-active factors. The cells are encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores, such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links.

Abstract translation: 公开了用于包封产生生物活性因子的活细胞的方法和系统。 通过将水性细胞悬浮液和聚合物溶液共挤出通过共同的口以形成具有封装细胞悬浮液的聚合物外涂层的管状挤出物，将细胞包封在半透膜聚合物膜内。 例如，细胞悬浮液和聚合物溶液可以通过具有至少两个同心孔的共同挤出口挤出，使得细胞悬浮液通过内孔挤出并且聚合物溶液通过外孔挤出。 聚合物溶液凝结形成外涂层。 当形成外涂层时，管状挤出物的端部可被密封以形成电池盒。 在一个实施方案中，管状挤出物间隔密封以限定通过聚合物连接物连接的分离的细胞室。

公开(公告)号：US5643773A

公开(公告)日：1997-07-01

申请号：US430786

申请日：1995-04-27

Applicant: Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

IPC: A61F2/02 ,  A61J3/07 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/22 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61J3/07 ,  A61K35/22 ,  A61K35/30 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/5089 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30 ,  Y10S530/817

Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biological material, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through an inner bore and the polymeric casting solution is extruded through an outer bore. Extrusion of the coagulant is initiated subsequent to initiating delivery of the casting solution to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time. This procedure can be modified to form in the capsule a coaxial rod that is connected to one end but not the other end of the capsule. This is accomplished by drawing casting solution into the inner bore after initiating extrusion of the casting solution through the outer bore, and then initiating delivery of the coagulant through the inner bore so as to coagulate the casting solution therein and form a rod, and ejecting the rod from the inner bore by pressure of the coagulant. Delivery of the coagulant and casting solution are then terminated as described above.

Abstract translation: 包含生物材料的细长无缝胶囊是通过一种方法制备的，其中包括细胞悬浮液或其它生物材料的凝结剂和聚合物浇铸溶液通过具有至少两个同心孔的共同挤出口挤出，使得凝结剂为 通过内孔挤出，并且聚合物浇铸溶液通过外孔挤出。 在引发浇铸溶液的输送之后开始凝结剂的挤出，以形成具有弯曲且光滑的前缘形状的胶囊。 然后关闭凝结剂的输送，并且立即或在一些预定时间之后终止浇注溶液的挤出。 该过程可以被修改以在胶囊中形成连接到胶囊的一端而不是另一端的同轴杆。 这是通过将铸造溶液通过外孔开始挤出之后将铸造溶液吸入内孔中，然后通过内孔引发凝结剂的输送，从而将铸造溶液凝结在其中并形成杆 通过凝结剂的压力从内孔中取出杆。 然后如上所述终止凝结剂和浇铸溶液的输送。

公开(公告)号：US5284761A

公开(公告)日：1994-02-08

申请号：US827728

申请日：1992-02-26

Applicant: Patrick Aebischer ,  Lars Wahlberg

Inventor： Patrick Aebischer ,  Lars Wahlberg

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K35/12 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K35/12 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61K2035/126 ,  A61K2035/128 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Methods and systems are disclosed for encapsulating viable cells which produce biologically-active factors. The cells are encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores, such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links.

Abstract translation: 公开了用于包封产生生物活性因子的活细胞的方法和系统。 通过将水性细胞悬浮液和聚合物溶液共挤出通过共同的口以形成具有封装细胞悬浮液的聚合物外涂层的管状挤出物，将细胞包封在半透膜聚合物膜内。 例如，细胞悬浮液和聚合物溶液可以通过具有至少两个同心孔的共同挤出口挤出，使得细胞悬浮液通过内孔挤出并且聚合物溶液通过外孔挤出。 聚合物溶液凝结形成外涂层。 当形成外涂层时，管状挤出物的端部可被密封以形成电池盒。 在一个实施方案中，管状挤出物间隔密封以限定通过聚合物连接物连接的分离的细胞室。

公开(公告)号：US5283187A

公开(公告)日：1994-02-01

申请号：US638759

申请日：1991-01-08

Applicant: Patrick Aebischer ,  Lars Wahlberg

Inventor： Patrick Aebischer ,  Lars Wahlberg

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K35/12 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08 ,  C12N11/12

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K35/12 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61K2035/126 ,  A61K2035/128 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Living cells such as animal cells which produce biologically active factors are encapsulated within a semipermeable, polymeric membrane such as polyacrylate by co-extruding an aqueous cell suspension and a polymeric solution through a common port having at least one concentric bores to form a tubular extrudate having a polymeric membrane which encapsulates the cell suspension. The cell suspension is extruded through an inner bore and the polymeric solution is extruded through an outer bore while a pressure differential is maintained between the cell suspension and the polymeric solution to impede solvent diffusion from the polymeric solution into the cell suspension. The polymeric solution coagulates to form an outer coating or membrane as the polymeric solution and the cell suspension are extruded through the extrusion port. As the outer membrane is formed, the ends of the tubular extrudate are sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links. In another embodiment, a cell capsule connected to a tethering filament is formed. The polymeric membrane may contain additives such as a surfactant, an anti-inflammatory agent or an anti-oxidant and can be coated with a protective barrier. The cell suspension may contain nutrients and an anchorage substrate.

Abstract translation: 活性细胞如产生生物活性因子的动物细胞被包封在半透性聚合物膜（例如聚丙烯酸酯）内，通过共混挤出水性细胞悬浮液和聚合物溶液通过具有至少一个同心孔的共同孔口形成管状挤出物， 封装细胞悬浮液的聚合物膜。 细胞悬浮液通过内孔挤出，并且聚合物溶液通过外孔挤出，同时在细胞悬浮液和聚合物溶液之间保持压力差以阻止溶剂从聚合物溶液扩散进入细胞悬液。 聚合物溶液凝聚形成外涂层或膜作为聚合物溶液，并且细胞悬浮液通过挤出端口挤出。 当外膜形成时，管状挤出物的端部被密封以形成细胞囊。 在一个实施方案中，管状挤出物间隔密封以限定通过聚合物连接物连接的分离的细胞室。 在另一个实施例中，形成连接到系链细丝的细胞囊。 聚合物膜可以含有添加剂如表面活性剂，抗炎剂或抗氧化剂，并且可以用保护屏障涂覆。 细胞悬浮液可以含有营养物和锚定基质。

公开(公告)号：US20070172454A1

公开(公告)日：2007-07-26

申请号：US11622284

申请日：2007-01-11

Applicant: Nicole Deglon ,  Patrick Aebischer ,  Jean-Charles Bensadoun

Inventor： Nicole Deglon ,  Patrick Aebischer ,  Jean-Charles Bensadoun

IPC: A61K48/00 ,  A61K38/20 ,  C12N15/867

CPC classification number: A61K38/204 ,  A61K48/00

Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.

Abstract translation: 本发明涉及IL-6R / IL-6嵌合体，突变蛋白，同种型，融合蛋白，功能衍生物，活性级分或环状置换衍生物或其盐在制备用于治疗和/ 或预防亨廷顿氏病。

公开(公告)号：US06800281B2

公开(公告)日：2004-10-05

申请号：US10008610

申请日：2001-11-08

Applicant: Patrick Aebischer ,  Susan Mary Kingsman ,  Stuart Naylor ,  Nicholas Mazarakis

Inventor： Patrick Aebischer ,  Susan Mary Kingsman ,  Stuart Naylor ,  Nicholas Mazarakis

IPC: A61K4800

CPC classification number: C12N15/86 ,  A61K48/00 ,  C07K14/4756 ,  C12N2740/15043

Abstract: Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.

Abstract translation: 公开并要求保护的是用于治疗或预防神经变性疾病，病症或疾病或症状或与之相关的生理学的方法，例如治疗或预防帕金森病或与之相关的症状或生理学，例如运动缺陷或黑质纹状体变性; 或用于诱导黑质纹状体再生。 有利地，所述方法包括施用表达GDNF的慢病毒载体，例如人GDNF，或其变体，同系物，类似物或衍生物。

公开(公告)号：US6083523A

公开(公告)日：2000-07-04

申请号：US148671

申请日：1998-09-04

Applicant: Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

Inventor： Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/18 ,  A61K39/395 ,  A61K47/36 ,  A61K48/00 ,  A61L27/00 ,  C12N5/00 ,  C12N5/071 ,  C12N5/077

CPC classification number: A61K9/0092 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/185 ,  A61K48/00 ,  A61K9/0024 ,  A61K9/4816 ,  C12N5/0012 ,  C12N5/0062 ,  C12N5/0614 ,  C12N5/0656 ,  C12N5/0677 ,  A61K2035/126 ,  A61K2035/128 ,  C12N2510/02 ,  Y10S514/814 ,  Y10S514/866

Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.

Abstract translation: 用于植入到产生所需产品或提供所需代谢功能的细胞个体中的免疫分析载体。 载体由含有分离的细胞和足以维持细胞的材料的核心区域组成，以及不含分离细胞的选择性选择性生物相容的外周区域，所述细胞免疫分离核心，但提供分泌产物或代谢功能的递送， 个人

公开(公告)号：US5554148A

公开(公告)日：1996-09-10

申请号：US453571

申请日：1995-05-26

Applicant: Patrick Aebischer ,  Paul C. DiCesare ,  Moses Goddard ,  Paul J. Mulhauser

Inventor： Patrick Aebischer ,  Paul C. DiCesare ,  Moses Goddard ,  Paul J. Mulhauser

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/22 ,  A61K35/12 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K35/12 ,  A61K35/30 ,  A61K38/1825 ,  A61K9/0024 ,  A61K9/0085 ,  A61M31/002 ,  B01J13/02 ,  C12N11/04 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  A61K2035/126 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Refillable immunoisolatory neurological therapy devices for local and controlled delivery of a biologically active factor to the brain of a patient. The devices include a cell chamber adapted for infusion with nsecretory cells and having at least one semipermeable or permselective surface across which biologically active factors secreted by the cells can be delivered to the brain. The devices also include means for introducing secretory cells into the cell chamber, and means for renewing the cells or cell medium.

Abstract translation: 用于局部和控制地将生物活性因子递送到患者脑部的可补充的免疫隔离神经治疗装置。 所述装置包括适于与分泌细胞一起输注并具有至少一个半透性或选择性选择性表面的细胞室，细胞分泌的生物活性因子可以被输送到脑。 所述装置还包括用于将分泌细胞引入细胞室的装置和用于更新细胞或细胞培养基的装置。